Oncolytics Biotech®. Takardar, mai suna "Oncolytic-matsakaici-matsakaicin ƙwayar cuta na ƙwayoyin CAR T guda biyu na musamman yana inganta inganci ga ingantaccen ciwace-ciwacen daji a cikin berayen," an buga shi a cikin Kimiyyar Fassarar Kimiyya tare da haɗin gwiwar masu bincike a manyan manyan cibiyoyi, ciki har da Mayo Clinic da Jami'ar Duke. Ana iya samun hanyar haɗi zuwa takarda ta danna nan.
"Samun waɗannan sakamakon da aka buga a cikin irin wannan babban jarida mai tasiri yana ba da muhimmiyar tabbacin waje game da muhimmancin su," in ji Thomas Heineman, MD, Ph.D., Babban Jami'in Harkokin Kiwon Lafiya na Oncolytics Biotech Inc. "Yayin da CAR T kwayoyin sun haifar da dogon lokaci. yana warkar da cututtuka na hematologic1, ƙwayoyin cuta na ƙwayoyin cuta na ƙwayoyin cuta masu ƙarfi (TMEs) na ciwon daji na gabobi sun iyakance tasirin su a cikin waɗannan alamun. An nuna Pelareorep akai-akai don juyar da TMEs na rigakafi, kuma a cikin littafin yanzu ana nuna pelareorep don ba da damar tasirin ƙwayoyin CAR T a cikin nau'ikan ƙwayar ƙwayar cuta mai ƙarfi. Wannan bincike ne mai ƙarfi wanda, idan an fassara shi zuwa asibiti, zai iya inganta haɓakar hasashen marasa lafiya da ke da nau'ikan cututtukan daji iri-iri masu yawa ta hanyar samar da sabon labari da zaɓin jiyya mai dorewa. Ta hanyar nuna ikon inganta juriyar ƙwayoyin T cell, rage tserewar antigen, da shawo kan ƙalubalen ƙalubalen TMEs, haɗa pelareorep yana magance mafi ƙalubalen shingaye uku don ingantaccen maganin CAR T.
Andrew de Guttadauro, Shugaban Oncolytics Biotech US kuma Shugaban Kasuwancin Kasuwanci na Duniya, ya kara da cewa, "Duk da juyin juya hali na maganin wasu cututtukan daji tare da wuce dala biliyan daya a tallace-tallace a bara, hanyoyin kwantar da hankali na CAR T a halin yanzu suna ba da hidima ga ƙananan marasa lafiya da ke fama da cutar jini. malignancies. Tare da waɗannan sabbin sakamakon, yanzu muna da tabbataccen shaida mai ƙarfi cewa pelareorep na iya buɗe ƙimar hanyoyin kwantar da hankali ta CAR T ta hanyar faɗaɗa yuwuwar kasuwancin su zuwa babbar kasuwar masu cutar kansa waɗanda ke fama da ciwace-ciwace.
Nazarin preclinical da aka buga a cikin takarda ya kimanta tsayin daka da ingancin ƙwayoyin CAR T da aka ɗora wa pelareorep ("CAR / Pela therapy") a cikin nau'ikan ƙwayar ƙwayar cuta mai ƙarfi. An kuma bincika sakamakon hada maganin CAR/Pela tare da kashi na gaba na pelareorep ("pelareorep boost"). Mahimman bayanai da ƙarshe daga takarda sun haɗa da:
• Nacewa da aikin rigakafin ciwon daji na ƙwayoyin CAR T sun inganta sosai lokacin da aka ɗora su da pelareorep. Idan aka kwatanta da ko dai magani kaɗai, jiyya tare da CAR/Pela far ya haifar da fa'idodin rayuwa mai mahimmanci a cikin fata na murine da ƙirar kansar ƙwaƙwalwa.
• Maganin CAR/Pela wanda ke biye da haɓakar pelareorep ya haifar da ingantaccen inganci a cikin fata na murine da nau'in ciwon daji na kwakwalwa da kuma maganin ƙari a cikin> 80% na berayen da aka kula da su a kowane samfurin.
• Load da ƙwayoyin CAR T tare da pelareoep ya haifar da ingantacciyar ƙwayar cutar kansa da kuma hana antigen tserewa a cikin vivo ta hanyar samar da ƙwayoyin CAR T tare da ƙayyadaddun ƙayyadaddun nau'ikan da suka yi niyya da antigen da aka tsara da kuma na asali na T cell receptor antigen. Waɗannan sakamakon sun nuna cewa CAR/Pela far na iya ba da fa'idodin warkewa mai dorewa idan aka kwatanta da jiyya tare da ƙwayoyin CAR T kaɗai.
Dokta Matt Coffey, Shugaba da Babban Jami'in Kamfanin Oncolytics Biotech Inc. kuma marubucin jaridar yayi sharhi, "Wadannan sakamako masu ban sha'awa misali ne mai kyau na yadda muke haɓaka haɗin gwiwa tare da manyan shugabannin ra'ayi da manyan cibiyoyin bincike don fadada damar pelareorep. tasirin warkewa. Wannan yana ba mu damar ci gaba da mai da hankali sosai kan shirin mu na ciwon nono, wanda ya nuna yadda ikon pelareorep na haɓaka kutsewar ƙwayar ƙwayar ƙwayar ƙwayar cuta ta haifar da haɗin gwiwa tare da masu hana wuraren bincike a asibiti. Waɗannan sabbin binciken bincike na gaskiya sun nuna fa'idodin haɗin gwiwa na pelareorep ya wuce har ma da masu hana wuraren bincike kuma suna ba da damar haɓaka yawan majinyatan da za a iya magance su. Yayin da muke neman wannan damar ta ci gaba, muna da niyyar yin amfani da dangantaka da abokan aikin ilimi ko masana'antu domin mu ci gaba da aiwatar da manufofin mu na asibiti da na kamfanoni tare da inganci."
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- An nuna Pelareorep akai-akai don juyar da TMEs na rigakafi, kuma a cikin littafin yanzu ana nuna pelareorep don ba da damar tasirin ƙwayoyin CAR T a cikin nau'ikan ƙwayar cuta mai ƙarfi.
- Load da ƙwayoyin CAR T tare da pelareoep ya haifar da ingantacciyar ƙwayar cutar kansa da kuma hana tserewa antigen a cikin vivo ta hanyar samar da ƙwayoyin CAR T tare da ƙayyadaddun ƙayyadaddun dual waɗanda ke keɓance antigen ɗin su da aka tsara da kuma antigen mai karɓar T cell na asali.
- Ta hanyar nuna ikon inganta juriya na ƙwayoyin T, rage tseren antigen, da shawo kan ƙalubalen ƙalubalen TMEs, haɗa da pelareorep yana magance manyan ƙalubalen shingaye uku don ingantaccen maganin CAR T.
